This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
With the addition of Karsanbhai, the Merck board will consist of 13 members
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
The collaboration offers opportunities for training, research fellowships, workshops and conferences at palliative care centers managed by Ajit Isaac Foundation
New research labs and process development services to enable next generation therapeutics
Performed within GENEWIZ from Azenta Life Sciences' CLIA-certified and CAP-accredited state-of-the-art clinical genomics laboratory
Emcure has launched an awareness campaign to help spread the word about male anemia
HYMPAVZI’s approval is based on Phase 3 study results demonstrating non-inferiority and superiority compared to routine prophylaxis in eligible patients with hemophilia A or B without inhibitors
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Subscribe To Our Newsletter & Stay Updated
